Difference between revisions of "Vascular sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "====Supportive medications" to "====Supportive therapy") |
m |
||
| Line 12: | Line 12: | ||
*<big>Regimens for [[Kaposi sarcoma|'''Kaposi sarcoma are here''']]</big>. | *<big>Regimens for [[Kaposi sarcoma|'''Kaposi sarcoma are here''']]</big>. | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=Guidelines= | =Guidelines= | ||
==[http://www.esmo.org/ ESMO]== | ==[http://www.esmo.org/ ESMO]== | ||
| − | |||
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://pubmed.ncbi.nlm.nih.gov/25210080 PubMed] | *[http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://pubmed.ncbi.nlm.nih.gov/25210080 PubMed] | ||
| − | |||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
| − | |||
*[https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma] | *[https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma] | ||
| − | |||
=Angiosarcoma, all lines of therapy= | =Angiosarcoma, all lines of therapy= | ||
| − | |||
==Bevacizumab monotherapy {{#subobject:3c01a5|Regimen=1}}== | ==Bevacizumab monotherapy {{#subobject:3c01a5|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
| − | |||
===Regimen {{#subobject:c663b6|Variant=1}}=== | ===Regimen {{#subobject:c663b6|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
| Line 36: | Line 29: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
| − | |||
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1 | *[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1 | ||
| − | |||
'''21-day cycles''' | '''21-day cycles''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
| − | |||
#'''NU 04S1:''' Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. [https://doi.org/10.1093/annonc/mds237 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22910841 PubMed] NCT00288015 | #'''NU 04S1:''' Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. [https://doi.org/10.1093/annonc/mds237 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22910841 PubMed] NCT00288015 | ||
| − | |||
==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== | ==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:ebf64d|Variant=1}}=== | ===Regimen {{#subobject:ebf64d|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
| Line 57: | Line 47: | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
| − | |||
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | ||
| − | |||
====Supportive therapy==== | ====Supportive therapy==== | ||
| − | |||
*[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | *[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | ||
*[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | *[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | ||
*[[Dexchlorpheniramine (Polaramine)]] 5 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | *[[Dexchlorpheniramine (Polaramine)]] 5 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | ||
*"Standard [[:Category:Emesis_prevention|antiemetics]] (mainly [[Metoclopramide (Reglan)]]) were prescribed as clinically indicated by the treating physician" | *"Standard [[:Category:Emesis_prevention|antiemetics]] (mainly [[Metoclopramide (Reglan)]]) were prescribed as clinically indicated by the treating physician" | ||
| − | |||
'''28-day cycle for 6 cycles''' | '''28-day cycle for 6 cycles''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
| − | |||
#'''ANGIOTAX:''' Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. [https://doi.org/10.1200/jco.2008.17.3146 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18809609 PubMed] | #'''ANGIOTAX:''' Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. [https://doi.org/10.1200/jco.2008.17.3146 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18809609 PubMed] | ||
| − | |||
==Pazopanib monotherapy {{#subobject:6hg776|Regimen=1}}== | ==Pazopanib monotherapy {{#subobject:6hg776|Regimen=1}}== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
===Regimen {{#subobject:1ug64d|Variant=1}}=== | ===Regimen {{#subobject:1ug64d|Variant=1}}=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 92: | Line 77: | ||
|} | |} | ||
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.'' | ''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.'' | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Pazopanib (Votrient)]] 800 mg PO once per day | *[[Pazopanib (Votrient)]] 800 mg PO once per day | ||
| − | |||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
| + | </div></div> | ||
===References=== | ===References=== | ||
#'''TAPPAS:''' Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. [https://doi.org/10.1001/jamaoncol.2021.3547 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35357396/ PubMed] NCT02979899 | #'''TAPPAS:''' Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. [https://doi.org/10.1001/jamaoncol.2021.3547 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35357396/ PubMed] NCT02979899 | ||
| − | |||
=Hemangioendothelioma, all lines of therapy= | =Hemangioendothelioma, all lines of therapy= | ||
| − | |||
=Hemangiopericytoma (solitary fibrous tumor), all lines of therapy= | =Hemangiopericytoma (solitary fibrous tumor), all lines of therapy= | ||
| − | |||
[[Category:Vascular sarcoma regimens]] | [[Category:Vascular sarcoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Soft tissue sarcomas]] | [[Category:Soft tissue sarcomas]] | ||
Revision as of 00:06, 1 March 2023
0 regimens on this page
0 variants on this page
|
- Note: this page contains regimens for several subtypes of vascular sarcoma. The following links will take you to disease-specific pages:
- Regimens for Kaposi sarcoma are here.
Guidelines
ESMO
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed
NCCN
Angiosarcoma, all lines of therapy
Bevacizumab monotherapy
Regimen
| Study | Evidence |
|---|---|
| Agulnik et al. 2013 (NU 04S1) | Phase 2 |
References
- NU 04S1: Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. link to original article contains dosing details in manuscript PubMed NCT00288015
Paclitaxel monotherapy
Regimen
| Study | Evidence |
|---|---|
| Penel et al. 2008 (ANGIOTAX) | Phase 2 |
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
Supportive therapy
- Dexamethasone (Decadron) 8 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 200 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Dexchlorpheniramine (Polaramine) 5 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- "Standard antiemetics (mainly Metoclopramide (Reglan)) were prescribed as clinically indicated by the treating physician"
28-day cycle for 6 cycles
References
- ANGIOTAX: Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. link to original article contains dosing details in manuscript PubMed
Pazopanib monotherapy
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Jones et al. 2022 (TAPPAS) | 2017-2019 | Phase 3 (C) | Pazopanib & Carotuximab | Did not meet primary endpoint of PFS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
References
- TAPPAS: Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. link to original article link to PMC article PubMed NCT02979899